Evidence map›Paper›PMID 21277903›Full record

ArticleJournal of virological methods2011

Silencing of HTLV-1 gag and env genes by small interfering RNAs in HEK 293 cells.

Rodrigo Haddad, Simone Kashima, Evandra Strazza Rodrigues, Rochele Azevedo, Patrícia Vianna Bonini Palma, Danielle Aparecida Rosa de Magalhães, Marco Antonio Zago, Dimas Tadeu Covas

Abstract read
In one paragraph

Article in Journal of virological methods, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.4field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Rodrigo HaddadUniversidade de São Paulo, Ribeirão Preto, São Paulo, Brazil.
Simone Kashima
Evandra Strazza Rodrigues
Rochele Azevedo
Patrícia Vianna Bonini Palma
Danielle Aparecida Rosa de Magalhães
Marco Antonio Zago
Dimas Tadeu Covas
Universidade de São Paulo · BRUniversidade de Ribeirão Preto · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Since the discovery of RNAi technology, several functional genomic and disease therapy studies have been conducted using this technique in the field of oncology and virology. RNAi-based antiviral therapies are being studied for the treatment of retroviruses such as HIV-1. These studies include the silencing of regulatory, infectivity and structural genes. The HTLV-1 structural genes are responsible for the synthesis of proteins involved in the entry, assembly and release of particles during viral infection. To examine the possibility of silencing HTLV-1 genes gag and env by RNA interference technology, these genes were cloned into reporter plasmids. These vectors expressed the target mRNAs fused to EGFP reporter genes. Three small interference RNAs (siRNAs) corresponding to gag and three corresponding to env were designed to analyze the effect of silencing by RNAi technology. The plasmids and siRNAs were co-transfected into HEK 293 cells. The results demonstrated that the expression of the HTLV-1 gag and env genes decreased significantly in vitro. Thus, siRNAs can be used to inhibit HTLV-1 structural genes in transformed cells, which could provide a tool for clarifying the roles of HTLV-1 structural genes, as well as a therapy for this infection.

Indexed as

Gene SilencingArtificial Gene FusionGene Products, envGene Products, gagGenes, ReporterGreen Fluorescent ProteinsHEK293 CellsHumansHuman T-lymphotropic virus 1RNA, Small Interferingenhanced green fluorescent proteinGene Products, envGene Products, gagGreen Fluorescent ProteinsRNA, Small Interfering

Identifiers

PMID21277903
PMCPMC7112899
OpenAlexW2014585689

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.